Prednisone and Acupuncture for the Treatment of Facial Neuritis: a Multiple Center, CER in China
Information source: Xijing Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bell's Palsy
Intervention: Prednisolone (Drug); acupuncture (Device); other treatment (Other)
Phase: N/A
Status: Recruiting
Sponsored by: Xijing Hospital Official(s) and/or principal investigator(s): Gang Zhao, MD, Study Director, Affiliation: the Department of Neurology , Xijing Hospital Feng Xia, MD, Study Chair, Affiliation: the Department of Neurology , Xijing Hospital
Overall contact: Gang Zhao, MD, Phone: 02984775361, Email: zhaogang@fmmu.edu.cn
Summary
The aim of this study is to compare the effects of prednisolone and staging acupuncture in
the recovery of the affected facial nerve, and to verify that whether in combination with
staging acupuncture is more effective than prednisolone alone for Bell's palsy in a large
number of patients.
Clinical Details
Official title: Prednisone Acetate and Acupuncture for the Treatment of Facial Neuritis: a Multiple Center, Comparative Effectiveness Research in China
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Assessment of Facial function
Secondary outcome: Neurology examinationregistration of ipsilateral pain
Detailed description:
Patients will be recruited between Sep, 2010, and Dec, 2014. Baseline assessments before the
start of treatment include neurological examination, grading of facial function, measurement
of ipsilateral pain, documentation of concurrent medication.
These patients are assigned to receive one of the following treatment groups, i. e. 1)the
hormone group: oral hormone drugs, do not accept acupuncture treatment; 2)acupuncture group:
using acupuncture therapy, do not accept oral hormone therapy; 3)hormone-acupuncture
combined treatment group: receive oral hormone and acupuncture therapy at the same time;
4)other treatment group: other treatment in addition to the above 3 groups of treatment
abroad. The secondary factor grouping (subgroup): According to the different time of
treatment after the onset of disease, the acupuncture group and the hormone- acupuncture
combined treatment group can be divided into Type Ⅰ subgroup (patients receive acupuncture
within 10 days of the onset of disease) and Type II subgroups (patients receive acupuncture
after 10 days of the onset of disease). The primary outcome is the time to complete recovery
of facial function, assessed by Sunnybrook system and House-Brackmann scale. The secondary
outcomes include the incidence of ipsilateral pain in the early stage of palsy (and the
duration of this pain), the proportion of patients with severe pain, the occurrence of
synkinesis, facial spasm or contracture, and the severity of residual facial symptoms during
the study period.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- involvement of unilateralfacial nerve paralysis only
- aged between 18 and 75 years old
- period of onset of facial paralysis within 72h
Exclusion Criteria:
- pregnancy
- breastfeeding
- being a woman of child bearing age who is unwilling to use contraceptives during the
medication period
- other neurological diseases
- diabetes
- badly controlled hypertension
- current or a history of serious heart disease
- history of renal or hepatic disease
- gastric or duodenal ulcer
- history of glaucoma
- acute otitis or history of ipsilateral chronic otitis
- history of tuberculosis, history of immunodeficiency syndromes
- recent head injury, psychiatric disease, or any other condition that is at risk of
being influenced by the study medication or that might have affected completion of the
study.
Locations and Contacts
Gang Zhao, MD, Phone: 02984775361, Email: zhaogang@fmmu.edu.cn
the Department of Neurology , Xijing Hospital, Xi'an, Shaanxi 710032, China; Recruiting Gang Zhao, MD, Phone: 02984775361, Email: zhaogang@fmmu.edu.cn Feng Xia, MD, Principal Investigator
Additional Information
Starting date: September 2010
Last updated: August 18, 2014
|